The Latest Breaking News from Influenza

Moderna Inc.’s (NASDAQ:MRNA) stock has surged approximately 37% in the last month but has dipped around 15% year to date.

Winter is here, and with it come higher rates of respiratory illnesses. If you’ve been struck down recently with a sore throat, runny nose and a cough, or perhaps even a fever, you’re not alone.

Decision to restrict thimerosal in immunizations could impact future vaccine availability on a global scale

ACIP panel to discuss influenza vaccines that contain thimerosal, which Kennedy called ‘dangerous’ in 2014 book

As winter settles over Australia, it’s not just the drop in temperature we notice – there’s also a sharp rise in respiratory illnesses. Most of us are familiar with the usual winter players such as COVID, influenza and RSV (respiratory syncytial virus), which often dominate news headlines and public health…

With a surge in winter respiratory infections, health experts are again urging Australians to get vaccinated for COVID-19 and influenza.

The Trump administration has canceled $766 million awarded to drugmaker Moderna Inc. to develop a vaccine against potential pandemic influenza viruses, including H5N1 bird flu

Avian influenza is no longer just an animal health issue, with rising mammal cases and severe ecosystem, trade, and food security impacts as outbreaks become more widespread and impact a broader range of species, a new report shows.

Late-stage trial data suggest that a new COVID-flu vaccine offers good protection against both infections, but experts expect the shot's approval may be delayed.